Volume 37, Issue 2 pp. 255-262
Experimental Cancer
Full Access

Production and characterization of monoclonal antibodies against human neuroblastoma

S. M. Schönmann

S. M. Schönmann

Institute of Clinical Protein Research, University of Bern, Switzerland

Search for more papers by this author
J. Iyer

J. Iyer

Institute of Clinical Protein Research, University of Bern, Switzerland

Search for more papers by this author
H. Laeng

H. Laeng

Institute of Pathology, University of Bern, Switzerland

Search for more papers by this author
H. A. Gerber

H. A. Gerber

Institute of Pathology, University of Bern, Switzerland

Search for more papers by this author
H. Käser

H. Käser

Institute of Clinical and Experimental Tumor Research, University of Bern, Switzerland

Search for more papers by this author
K. Blaser

K. Blaser

Institute of Clinical Protein Research, University of Bern, Switzerland

Search for more papers by this author
First published: 15 February 1986
Citations: 22

Abstract

MAb were derived from mice immunized with cells of the human neuroblastoma line IMR-32. Five hybridomas were selected according to their selective binding to human cell lines, tumors and normal tissues. One of them, CE7, reacted with all sympatho-adreno-medullary cells (neuroblastoma, ganglioneuroblastoma, ganglioneuroma, pheochromocytoma, adrenal medulla, sympathetic ganglion cells). Weak cross-reactivities were observed with melanocytes and with some human melanoma and glioma cell lines. The antigen recognized by CE7 was markedly expressed on neuroblastoma tumors of all histological grades, independently of the adrenergic or cholinergic nature of these cells. MAb derived from clones AD2, BCI, BC4 and CB10 bound variably to some, but not to all, neuroblastoma cells. By using these MAb, 3 phenotypes of neuroblastoma lines could be distinguished. The binding profiles of these types, however, showed no correlation with origin of the cell lines or stage of the disease.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.